A clinical grade sequencing-based assay for CEBPA mutation testing: Report of a large series of myeloid neoplasms

Journal of Molecular Diagnostics

Volumn 17, Issue 1, 2015, Pages 76-84

  Behdad, Amir ^a   Weigelin, Helmut C ^a   Elenitoba Johnson, Kojo S J ^a   Betz, Bryan L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEBPA PROTEIN; FLT3 LIGAND; GENOMIC DNA; NUCLEOPHOSMIN; PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AMPLICON; ARTICLE; CANCER DIAGNOSIS; EXON; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN; INDEL MUTATION; KARYOTYPE; LEUKEMIA RELAPSE; MISSENSE MUTATION; MUTATION RATE; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TRINUCLEOTIDE REPEAT;

EID: 84963952136     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2014.09.007     Document Type: Article

References (34)

1. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, and A. Goldstone The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333
2. M. Klaus, T. Haferlach, S. Schnittger, W. Kern, W. Hiddemann, and C. Schoch Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization Cancer Genet Cytogenet 155 2004 47 56
3. J.C. Byrd, K. Mrozek, R.K. Dodge, A.J. Carroll, C.G. Edwards, D.C. Arthur, M.J. Pettenati, S.R. Patil, K.W. Rao, M.S. Watson, P.R. Koduru, J.O. Moore, R.M. Stone, R.J. Mayer, E.J. Feldman, F.R. Davey, C.A. Schiffer, R.A. Larson, and C.D. Bloomfield Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
4. D. Grimwade, H. Walker, G. Harrison, F. Oliver, S. Chatters, C.J. Harrison, K. Wheatley, A.K. Burnett, and A.H. Goldstone The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 98 2001 1312 1320
5. D.C. Arthur, R. Berger, H.M. Golomb, G.J. Swansbury, B.R. Reeves, G. Alimena, H. Van Den Berghe, C.D. Bloomfield, A. de la Chapelle, G.W. Dewald, O.M. Garson, A. Hagemeijer, Y. Kaneko, F. Mitelman, R.V. Pierre, T. Ruutu, M. Sakurai, S.D. Lawler, and J.D. Rowley The clinical significance of karyotype in acute myelogenous leukemia Cancer Genet Cytogenet 40 1989 203 216
6. K. Mrozek, N.A. Heerema, and C.D. Bloomfield Cytogenetics in acute leukemia Blood Rev 18 2004 115 136
7. R.F. Schlenk, K. Dohner, J. Krauter, S. Frohling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Spath, M. Morgan, A. Benner, B. Schlegelberger, G. Heil, A. Ganser, and H. Dohner Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
8. D.G. Tenen, R. Hromas, J.D. Licht, and D.E. Zhang Transcription factors, normal myeloid development, and leukemia Blood 90 1997 489 519
9. D.E. Zhang, P. Zhang, N.D. Wang, C.J. Hetherington, G.J. Darlington, and D.G. Tenen Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice Proc Natl Acad Sci U S A 94 1997 569 574
10. T. Pabst, B.U. Mueller, P. Zhang, H.S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D.G. Tenen Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia Nat Genet 27 2001 263 270
11. S. Frohling, R.F. Schlenk, I. Stolze, J. Bihlmayr, A. Benner, S. Kreitmeier, K. Tobis, H. Dohner, and K. Dohner CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations J Clin Oncol 22 2004 624 633
12. C.L. Green, K.K. Koo, R.K. Hills, A.K. Burnett, D.C. Linch, and R.E. Gale Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations J Clin Oncol 28 2010 2739 2747
13. A. Dufour, F. Schneider, K.H. Metzeler, E. Hoster, S. Schneider, E. Zellmeier, T. Benthaus, M.C. Sauerland, W.E. Berdel, T. Buchner, B. Wormann, J. Braess, W. Hiddemann, S.K. Bohlander, and K. Spiekermann Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome J Clin Oncol 28 2010 570 577
14. A. Fasan, C. Haferlach, T. Alpermann, S. Jeromin, V. Grossmann, C. Eder, S. Weissmann, F. Dicker, A. Kohlmann, S. Schindela, W. Kern, T. Haferlach, and S. Schnittger The role of different genetic subtypes of CEBPA mutated AML Leukemia 28 2014 794 803
15. T. Benthaus, F. Schneider, G. Mellert, E. Zellmeier, S. Schneider, P.M. Kakadia, W. Hiddemann, S.K. Bohlander, M. Feuring-Buske, J. Braess, K. Spiekermann, and A. Dufour Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia Br J Haematol 143 2008 230 239
16. L.I. Lin, T.C. Lin, W.C. Chou, J.L. Tang, D.T. Lin, and H.F. Tien A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias Leukemia 20 2006 1899 1903
17. L.I. Lin, C.Y. Chen, D.T. Lin, W. Tsay, J.L. Tang, Y.C. Yeh, H.L. Shen, F.H. Su, M. Yao, S.Y. Huang, and H.F. Tien Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells Clin Cancer Res 11 2005 1372 1379
18. O. Fuster, E. Barragan, P. Bolufer, E. Such, A. Valencia, M. Ibanez, S. Dolz, I. de Juan, A. Jimenez, M.T. Gomez, I. Buno, J. Martinez, J. Cervera, P. Montesinos, F. Moscardo, and M.A. Sanz Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia Ann Hematol 91 2012 1 7
19. J.Y. Ahn, K. Seo, O. Weinberg, S.D. Boyd, and D.A. Arber A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia J Mol Diagn 11 2009 319 323
20. B.J. Wouters, I. Louwers, P.J. Valk, B. Lowenberg, and R. Delwel A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML Blood 109 2007 389 390
21. T. Pabst, M. Eyholzer, J. Fos, and B.U. Mueller Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis Br J Cancer 100 2009 1343 1346
22. B.J. Wouters, B. Lowenberg, C.A. Erpelinck-Verschueren, W.L. van Putten, P.J. Valk, and R. Delwel Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 2009 3088 3091
23. V. Grossmann, S. Schnittger, S. Schindela, H.U. Klein, C. Eder, M. Dugas, W. Kern, T. Haferlach, C. Haferlach, and A. Kohlmann Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology J Mol Diagn 13 2011 129 136
24. L. Tizzani, M. Wesolowski-Louvel, V. Forte, F. Romitelli, F. Salani, M. Lemaire, H. Neil, and M.M. Bianchi Mutations of the RAG3 gene encoding a regulator of fermentation in Kluyveromyces lactis are suppressed by a mutation of the transcription factor gene KlGCR1 FEMS Yeast Res 7 2007 675 682
25. V. Biggio, A. Renneville, O. Nibourel, N. Philippe, L. Terriou, C. Roumier, P. Amouyel, D. Cottel, S. Castaigne, H. Dombret, X. Thomas, P. Fenaux, and C. Preudhomme Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML Leukemia 22 2008 655 657
26. A.F. Gombart, W.K. Hofmann, S. Kawano, S. Takeuchi, U. Krug, S.H. Kwok, R.J. Larsen, H. Asou, C.W. Miller, D. Hoelzer, and H.P. Koeffler Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias Blood 99 2002 1332 1340
27. C. Preudhomme, C. Sagot, N. Boissel, J.M. Cayuela, I. Tigaud, S. de Botton, X. Thomas, E. Raffoux, C. Lamandin, S. Castaigne, P. Fenaux, and H. Dombret Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Blood 100 2002 2717 2723
28. S. Barjesteh van Waalwijk van Doorn-Khosrovani, C. Erpelinck, J. Meijer, S. van Oosterhoud, W.L. van Putten, P.J. Valk, H. Berna Beverloo, D.G. Tenen, B. Lowenberg, and R. Delwel Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML Hematol J 4 2003 31 40
29. J. Snaddon, M.L. Smith, M. Neat, M. Cambal-Parrales, A. Dixon-McIver, R. Arch, J.A. Amess, A.Z. Rohatiner, T.A. Lister, and J. Fitzgibbon Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2 Genes Chromosomes Cancer 37 2003 72 78
30. L.Y. Shih, C.F. Huang, T.L. Lin, J.H. Wu, P.N. Wang, P. Dunn, M.C. Kuo, and T.C. Tang Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia Clin Cancer Res 11 2005 1821 1826
31. T. Pabst, M. Eyholzer, S. Haefliger, J. Schardt, and B.U. Mueller Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia J Clin Oncol 26 2008 5088 5093
32. M. Bienz, M. Ludwig, E.O. Leibundgut, B.U. Mueller, D. Ratschiller, M. Solenthaler, M.F. Fey, and T. Pabst Risk assessment in patients with acute myeloid leukemia and a normal karyotype Clin Cancer Res 11 2005 1416 1424
33. A. Dufour, F. Schneider, E. Hoster, T. Benthaus, B. Ksienzyk, S. Schneider, P.M. Kakadia, M.C. Sauerland, W.E. Berdel, T. Buchner, B. Wormann, J. Braess, M. Subklewe, W. Hiddemann, S.K. Bohlander, and K. Spiekermann Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients Ann Hematol 91 2012 1051 1063
34. J.P. Patel, M. Gonen, M.E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, P. Van Vlierberghe, I. Dolgalev, S. Thomas, O. Aminova, K. Huberman, J. Cheng, A. Viale, N.D. Socci, A. Heguy, A. Cherry, G. Vance, R.R. Higgins, R.P. Ketterling, R.E. Gallagher, M. Litzow, M.R. van den Brink, H.M. Lazarus, J.M. Rowe, S. Luger, A. Ferrando, E. Paietta, M.S. Tallman, A. Melnick, O. Abdel-Wahab, and R.L. Levine Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089